Vertex Pharmaceuticals price target raised to $450 from $433 at Scotiabank
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform ...
Vertex Pharmaceuticals upgraded to Hold from Sell at Canaccord yesterday
As previously reported yesterday afternoon, Canaccord upgraded Vertex Pharmaceuticals (VRTX) to Hold from Sell with a price target of $424, up ...
Vertex Pharmaceuticals upgraded to Hold from Sell at Canaccord
Canaccord upgraded Vertex Pharmaceuticals (VRTX) to Hold from Sell with a price target of $424, up from $408.Maximize Your Portfolio with Data ...
Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
Earnings week ahead: MCD, KO, CSCO, PARA, MRNA, ROKU, SMCI, CVS, SHOP and more
As the quarterly earnings season continues, the upcoming week promises a flurry of reports from some of the most influential companies spanning various industries. In the consumer sector, Coca-Cola ...
Yahoo13d
Mid-air collision kills 67 people in deadliest U.S. air disaster in a quarter century
34,612 people played the daily Crossword recently. Can you solve it faster than others?34,612 people played the daily Crossword recently. Can you solve it faster than others? I Was Willing To Do ...
US FDA approves Vertex's non-opioid painkiller
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...
Nasdaq14d
VRTX Factor-Based Stock Analysis
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...